CA2166730A1 - Combinaisons d'un agent de motilite gastro-intestinal et d'un antagoniste des recepteurs h2 - Google Patents

Combinaisons d'un agent de motilite gastro-intestinal et d'un antagoniste des recepteurs h2

Info

Publication number
CA2166730A1
CA2166730A1 CA 2166730 CA2166730A CA2166730A1 CA 2166730 A1 CA2166730 A1 CA 2166730A1 CA 2166730 CA2166730 CA 2166730 CA 2166730 A CA2166730 A CA 2166730A CA 2166730 A1 CA2166730 A1 CA 2166730A1
Authority
CA
Canada
Prior art keywords
cisapride
mgs
relief
gastrointestinal
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2166730
Other languages
English (en)
Inventor
Robert T. Sims
William Slivka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Johnson and Johnson Consumer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2166730A1 publication Critical patent/CA2166730A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des préparations pharmaceutiques destinées à la prévention, au traitement et au soulagement des indigestions, de l'hyperacidité gastrique, des brûlures épigastriques, des reflux gastro-oesophagiens, des dyspepsies, des constipations, des excès et autres troubles gastro-intestinaux des mammifères, y compris de l'homme, par administration de composés associant: (i) une quantité d'anti-H2 suffisante pour soulager les désordres gastro-intestinaux ou oesophagiens, l'anti-H2 étant sélectionné dans la famille de composés dont la formulation est (I) ainsi que de leurs dérivés sous forme de sels, d'hydrates, de stéréoisomères ou de polymorphes de qualité pharmaceutiques; (ii) un agent facilitant la motilité gastro-intestinale tel que le cisapride, en quantité suffisante pour soulager les troubles gastro-intestinaux ou oesophagiens et accélérer le transit gastro-duodénal; et le cas échéant (iii) du siméthicone ou de l'alpha-D-galactosidase en quantité suffisante pour soulager les flatulences.
CA 2166730 1993-07-06 1994-07-05 Combinaisons d'un agent de motilite gastro-intestinal et d'un antagoniste des recepteurs h2 Abandoned CA2166730A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8759093A 1993-07-06 1993-07-06
US087,590 1993-07-06

Publications (1)

Publication Number Publication Date
CA2166730A1 true CA2166730A1 (fr) 1995-01-19

Family

ID=22206098

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2166730 Abandoned CA2166730A1 (fr) 1993-07-06 1994-07-05 Combinaisons d'un agent de motilite gastro-intestinal et d'un antagoniste des recepteurs h2

Country Status (5)

Country Link
EP (1) EP0707492A1 (fr)
JP (1) JPH08512322A (fr)
AU (1) AU7397194A (fr)
CA (1) CA2166730A1 (fr)
WO (1) WO1995001803A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4770593A (en) * 1992-07-07 1994-01-31 Sepracor, Inc. Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
EP0649307A4 (fr) * 1992-07-07 1996-06-26 Sepracor Inc Procedes d'utilisation de cisapride (-) pour le traitement du reflux gastro- sophagien et d'autres troubles.
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
EP0866707A1 (fr) * 1995-12-01 1998-09-30 Janssen Pharmaceutica N.V. Liberation retard de cisapride
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
EP0803251B1 (fr) * 1996-04-23 2002-07-17 Janssen Pharmaceutica N.V. Formes solides d'administration de cisapride à libération immédiate et indépendente du PH
US6147093A (en) 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
JP2002504107A (ja) * 1997-06-11 2002-02-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ （＋）−または（−）−シサプリドの即時放出性ｐＨ非依存的固形投薬剤形
IT1298269B1 (it) * 1998-02-18 1999-12-20 Promefarm S R L Uso di un polietilenglicole come mezzo di contrasto in ecografia
CN1312716A (zh) 1998-06-15 2001-09-12 塞普拉科有限公司 光学纯度(－)—降西沙必利对治疗呼吸暂停、贪食症和其它疾病的用途
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6676933B2 (en) 2001-05-23 2004-01-13 Osmotica Corp. Pharmaceutical composition containing mosapride and pancreatin
US6986901B2 (en) * 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions
AU2005204014B2 (en) * 2004-01-06 2008-02-28 Panacea Biotec Ltd. Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
CO5790164A1 (es) * 2006-08-10 2007-08-31 Procaps S A Composicion farmaceutica solida que incluye en combinacion un agente regulador de la motilidad intestinal y un agente antiflatulento
MX2010012479A (es) * 2010-11-16 2012-05-16 Posi Visionary Solutions Llp Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion.
MX2010012480A (es) * 2010-11-16 2012-05-16 Posi Visionary Solutions Llp Composicion farmaceutica adaptada para administrarse oralmente y proceso para su preparación para su prevencion y tratamiento, del sindrome del intestino irritable, a base de un odificador dela motalidad intestinal y a-d- galactosidasa.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229137A (en) * 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn

Also Published As

Publication number Publication date
WO1995001803A1 (fr) 1995-01-19
EP0707492A1 (fr) 1996-04-24
JPH08512322A (ja) 1996-12-24
AU7397194A (en) 1995-02-06

Similar Documents

Publication Publication Date Title
CA2166730A1 (fr) Combinaisons d'un agent de motilite gastro-intestinal et d'un antagoniste des recepteurs h2
AU627775B2 (en) Pharmaceutical compositions
CN1108153C (zh) 含奥丹亚龙的口服组合物
MXPA04006912A (es) Formas de dosis de bencimidazol substituidas novedosas y metodo para usar las mismas.
EP0533281B1 (fr) Utilisation de ranitidine bismuth citrate en combinaison avec claritromycin ou claritromycin et tetracycline, pour la fabrication d'un médicament pour le traitement des maladies gastrointestinales
JP2003523324A (ja) 組合せ医薬および胃腸疾患の処置へのそれらの使用
EP0550083B1 (fr) Médicaments pour le traitement de conditions inflammatoires ou pour l'analgésie contenants un NSAID et du citrate de bismuth-ranitidine
JP2012021025A (ja) メロキシカムを含む組成物
US5348744A (en) Antidiarrheal compositions containing loperamide hydrochloride and a saccharide
JP2002525266A (ja) 感染性潰瘍又は胃炎に対するタウロリジン及び／又はタウルルタム
EP0707484A1 (fr) Combinaison antiacide-alginate-antagoniste h 2?
WO1995001780A1 (fr) Combinaisons alginate-antagoniste de h¿2?
US20050038018A1 (en) Meloxicam compositions
KR100550839B1 (ko) 항균제
WO1995001792A1 (fr) Composes anti-h2-antihistaminiques
JP2006506367A (ja) ヘリコバクター・ピロリ関連疾患の治療方法
WO1995001784A1 (fr) Composes anti-flatulences a base d'antagoniste d'h2 et de sucralfate
WO1995016446A1 (fr) Composes a base de ranitidine
KR101153571B1 (ko) 테나토프라졸 및 히스타민 ｈ2-수용체 길항제를 배합한제약 조성물
JPH10511637A (ja) ヒスタミンｈ▲下２▼−アンタゴニストの吸収を増強するためのグルコースのようなパラセルラー吸収エンハンサーの使用
JP2008255008A (ja) 滑膜細胞増殖抑制剤
AU677108B2 (en) Ranitidine and calcium carbonate pharmaceutical combination product
AU690664B2 (en) Low dosage ranitidine compositions for the treatment of minor gastrointestinal disorders associated with excess acid secretion
Eddlestone Drug Therapies Used in Gastrointestinal
US20100130553A1 (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxido-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in the treatment of cranial traumas

Legal Events

Date Code Title Description
FZDE Dead